Stay updated on Biomarker Analysis in Urothelial Cancer Clinical Trial

Sign up to get notified when there's something new on the Biomarker Analysis in Urothelial Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Biomarker Analysis in Urothelial Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the response rates of immune checkpoint inhibitors like Pembrolizumab in second-line treatments for urothelial cancer patients, with a focus on identifying drivers of local immune suppression for improved patient selection and treatment strategies.
    Difference
    0.1%
    Check dated 2024-06-06T14:29:55.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments. Additionally, it now includes a reference to another clinical trial (CPCT-02) and specifies the requirement for informed consent.
    Difference
    48%
    Check dated 2024-05-22T21:10:01.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:27:55.000Z thumbnail image

Stay in the know with updates to Biomarker Analysis in Urothelial Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Biomarker Analysis in Urothelial Cancer Clinical Trial page.